Insider Trading March 5, 2026

Delek US CEO Executes $2.05 Million Stock Sale as Shares Trade Near Yearly High

Avigal Soreq sold 50,000 shares under a pre-arranged 10b5-1 plan; company posted an EPS beat but revenue missed guidance for Q4 2025

By Derek Hwang DK
Delek US CEO Executes $2.05 Million Stock Sale as Shares Trade Near Yearly High
DK

Delek US Holdings President and CEO Avigal Soreq sold 50,000 shares on March 3, 2026, generating roughly $2.05 million in proceeds through three transactions executed under a 10b5-1 plan. The stock has climbed sharply over the past year and is trading near its 52-week high, while independent analysis flags the shares as overvalued versus Fair Value. The firm also reported a strong fourth-quarter 2025 EPS outperformance, although revenue fell short of expectations.

Key Points

  • Delek US Holdings CEO Avigal Soreq sold 50,000 shares on March 3, 2026, realizing about $2,054,157 in total proceeds; the sale occurred in three separate transactions under a 10b5-1 trading plan established December 3, 2025.
  • After the transactions, Soreq directly owns 251,678 shares of the company; the stock is trading near its 52-week high of $45.74 after a roughly 216% one-year gain.
  • Delek reported Q4 2025 EPS of $2.31, far exceeding expectations of a $0.07 loss, while revenue of $2.43 billion missed the $2.55 billion consensus; independent analysis cited in research flags the stock as overvalued relative to Fair Value.

Avigal Soreq, President and Chief Executive Officer of Delek US Holdings (NASDAQ:DK), disposed of 50,000 shares of common stock on March 3, 2026, for a total of approximately $2,054,157. The sale was carried out in three tranches and occurred while the stock was trading close to its 52-week high of $45.74, following a roughly 216% return over the previous 12 months.

The transactions were split across three executions. The first tranche consisted of 13,768 shares sold at a weighted average price of $41.71, with execution prices ranging from $41.36 to $42.35. The second tranche involved 34,332 shares sold at an average price of $40.90, with prices spanning $40.34 to $41.34. The final tranche saw 1,900 shares sold at an average of $39.85, with trade prices between $39.70 and $40.33.

Following these sales, Soreq's direct ownership in Delek US Holdings stands at 251,678 shares. The dispositions were made pursuant to a pre-arranged 10b5-1 trading plan that was adopted on December 3, 2025.

Independent valuation analysis referenced in available research indicates the stock currently appears overvalued relative to its Fair Value. That same research source offers a Pro Research Report that covers Delek and more than 1,400 other U.S. equities for readers seeking additional valuation and performance detail.


In corporate results released for the fourth quarter of 2025, Delek US Holdings reported earnings per share of $2.31. That EPS figure materially outpaced analyst expectations, which had forecast a loss of $0.07 per share, representing a positive surprise of approximately 3,400% relative to the consensus estimate.

Revenue for the quarter was $2.43 billion, coming in below the $2.55 billion that analysts had expected. That shortfall equated to a negative surprise of about 4.71%. The combined outcome - a sizeable EPS beat alongside a revenue miss - highlights divergent performance signals in the quarter, with profitability metrics stronger than anticipated while top-line receipts lagged forecasts.

The earnings release and the insider sale have drawn attention among market participants and analysts. The information available does not specify any immediate analyst rating changes tied to the results, though the sizable EPS beat is likely to factor into market assessments going forward. Investors and observers will be watching for subsequent developments and additional disclosures from the company.

Risks

  • Valuation risk - Independent analysis indicates the stock appears overvalued relative to its Fair Value, which may affect investor sentiment in the equities market.
  • Revenue shortfall - Q4 2025 revenue missed expectations, introducing uncertainty about top-line momentum and its impact on future earnings and market assessments.
  • Insider selling timing - While the sales were conducted under a pre-arranged 10b5-1 plan, large insider dispositions occurring near a 52-week high can raise questions among investors about near-term outlook; this could influence trading dynamics in the stock.

More from Insider Trading

Huntington Ingalls Executive Sells $736,848 in Stock; Company Posts Q4 Beats and Analyst Target Adjustments Mar 5, 2026 Columbia Banking SVP Disposes of $127,932 in Shares Under Prearranged Plan Mar 5, 2026 Cytokinetics EVP Executes $1.6M Stock Sale, Exercises Options for 26,000 Shares Mar 5, 2026 United Therapeutics Director Sells Small Stake, Exercises Options as Analysts Raise Targets Mar 5, 2026 Zebra Technologies CMO makes small stock sale amid larger March equity activity Mar 5, 2026